Unveiling 7 Analyst Insights On Avidity Biosciences
Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Avidity Biosciences(RNA.US) Officer Sells US$4.5 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Officer Flanagan W. Michael sold 111.39K shares of common stock on Sep 11, 2024 at an average price of $40.3993 for a total value of $4.5 million.Source: Announcement
Avidity Biosciences Insider Sold Shares Worth $1,010,043, According to a Recent SEC Filing
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Wells Fargo analyst Yanan Zhu maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 33.5% and
Avidity Biosciences: Strong Buy on Promising Clinical Data and Reduced Competition
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays analyst Gena Wang maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7% and a
Avidity Biosciences to Participate in Upcoming Investor Conferences
Barclays Initiates Avidity Biosciences at Overweight
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Barclays analyst Gena Wang initiates coverage on $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7%
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Life Science Cares San Diego Scales Partnership With Avidity Biosciences Through Life Science Shares Program
Avidity Biosciences Is Maintained at Outperform by Evercore ISI Group
Avidity Biosciences Price Target Cut to $53.00/Share From $54.00 by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Avidity Biosciences Analyst Ratings
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore analyst Gavin Clark-Gartner maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and adjusts the target price from $54 to $53.According to TipRanks data, the analyst has a success
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
Express News | Avidity Biosciences Inc : Evercore ISI Cuts Target Price to $53 From $54